Retracted: Aiming for Clinical Remission in Asthma: The Next Frontier

Authors: *William Busse,¹ Geoffrey Chupp²

1. Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA
2. Division of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, Connecticut, USA

Disclosure: Busse has received honoraria from AstraZeneca, GlaxoSmithKline (GSK), Regeneron Pharmaceuticals, and Sanofi-Genzyme for speaking and consultancy services; and has held grants from National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID) and NIH-National Heart, Lung, and Blood Institute (NHLBI). Chupp has received honoraria from GSK, AstraZeneca, Genentech, Novartis, Sanofi-Genzyme, Regeneron Pharmaceuticals, and Teva Pharmaceuticals.

Acknowledgements: Medical writing assistance provided by Caroline E. Cross, Reading, UK.

Disclaimer: The opinions expressed in this article belong solely to the named speakers. For mepolizumab prescribing information, please navigate to the appendix at the end of the article.

Support: The symposium and publication of this article was supported by GSK Respiratory

Keywords: Asthma, biologics, exacerbations, lung function, remission, severe asthma.

Citation: EMJ Respir. 2023;11[Suppl 1]:2-10. DOI/10.33590/emjrespir/10306104. https://doi.org/10.33590/emjrespir/10306104.

This article has now been retracted and a retraction statement has been published.

Retraction: Aiming for Clinical Remission in Asthma: The Next Frontier